HematologyNews.net

Hematology Xagena

A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma ( DLBCL ) are more likely to respond to the drug Ibrutinib ( Imbruvica ) than patients with ...


The benefit of Azacitidine treatment in survival of high-risk myelodysplastic syndromes ( MDS ) patients compared with conventional care treatment ( CCT ) has not been established outside clinical tri ...


Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto ) in adults with relapsed or refractory Philadelphia chromosome-positive ( ...


A phase 2 trial of the investigational medicine Venetoclax met its primary endpoint ( overall response rates ) in patients with relapsed / refractory or previously untreated chronic lymphocytic leukem ...


PF-05082566 ( PF-2566 ) is an investigational immunotherapy and fully humanized monoclonal antibody administered intravenously that stimulates signaling through 4-1BB ( CD-137 ), a protein expressed i ...


Results from a sub-analysis of the phase 2 RESONATE-17 study has shown Ibrutinib ( Imbruvica ) was associated with robust efficacy and a positive risk-benefit profile in patients with relapsed or refr ...


Initial treatment of acute promyelocytic leukaemia traditionally involves Tretinoin ( all-trans retinoic acid ) combined with anthracycline-based risk-adapted chemotherapy, with Arsenic trioxide being ...


Ninety-three percent of pediatric patients ( 55 of 59 ) with relapsed/refractory acute lymphoblastic leukemia ( ALL ) went into remission after receiving an investigational therapy made from their own ...


Merck, known as MSD outside the United States and Canada, has announced new study findings investigating the use of Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Lenalidomide a ...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as Crizot ...


Positive top-line results of the Kids B-LONG phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [ Coagulation Factor IX ( Recombinant ), Fc Fusion Protein ] in ...


Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia ( CLL ) responded to the therapy, with some complete remissio ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


The FDA ( Food and Drug Administration ) has approved Farydak ( Panobinostat, previously known as LBH589 ) capsules in combination with Bortezomib ( Velcade ) and Dexamethasone for the treatment of pa ...


Vitamin D is increasingly recognized for its roles in non-skeletal disorders. Patients with sickle cell disease ( SCD ) have a high prevalence of vitamin D deficiency but data are limited with respect ...